Walter H. Moos, Ph.D., was appointed CEO of ShangPharma Innovation.
Intouch Solutions proudly announces the promotions of both Vicky Cory and Krisha Newham to vice president of client services.
Nearly nine months after slashing 25 percent of the company’s workforce, Iroko Pharmaceuticals is terminating more than 100 full-time and part-time employees.
A little more than two weeks after being placed on administrative leave, Gur Roshwalb – chief executive officer of Akari Therapeutics – resigned his position.
Novartis AG, headquartered in Basel, Switzerland, filed with the state of New Jersey that it plans to lay off more than 200 workers. The company, whose U.S. headquarters are in East Hanover, NJ, is undergoing operational changes.
Novartis AG is shaking up its operations by terminating approximately 500 production and development positions in Switzerland, but adding an additional 350 jobs to its growing biotech business, Matthias Leuenberger said in a posting on the company’s Swiss site.
Greater Than One Inc. (GTO) announced the appointment of Kieran Walsh as President of its US operations. Walsh is responsible for leading the GTO staff and offices in New York and San Francisco, and for providing oversight on all US-based accounts.
NYC-based FCB Health appointed Kim Barke to the role of group creative director to lead its oncology accounts.
As Teva Pharmaceutical narrows down its candidate for a new chief executive officer, the company is shuttering a plant in Hungary and laying off 500 employees, according to reports.
Danish drugmaker Novo Nordisk said the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to “a potential conflict of interest.”